A Phase IIa Study of Neoadjuvant JX-594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion or Intratumoral Injection Followed by Surgical Resection in Patients With Metastatic Colorectal Tumors Within the Liver.

Trial Profile

A Phase IIa Study of Neoadjuvant JX-594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion or Intratumoral Injection Followed by Surgical Resection in Patients With Metastatic Colorectal Tumors Within the Liver.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2013

At a glance

  • Drugs Pexastimogene devacirepvec (Primary) ; Pexastimogene devacirepvec (Primary)
  • Indications Colorectal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 03 Feb 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Nov 2011 Planned End Date changed from 1 Sep 2013 to 1 Oct 2013, according to ClinicalTrials.gov record.
    • 24 Oct 2011 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top